To synthesize the Council on Strategic Risks' 2025 AIxBio analysis and the CEPI Biosecurity Strategy Implementation Plan (2025-2026) into a comprehensive framework for governing the convergence of AI capabilities and biological research, with specific focus on cyberbiosecurity legislation and dual-use research oversight.

Synthesis of Council on Strategic Risks AIxBio 2025 Year in Review (December 2025), CEPI Biosecurity Strategy Implementation Plan (2025-2026), Biosecurity 2026 analysis by Olvera (Lawrence Livermore National Laboratory, February 2026), and Hilaris Publishers global biosecurity framework analysis. Cross-referenced with FY 2026 NDAA biosecurity provisions.

The convergence of AI and biology — the "AIxBio" threat surface — represents the most consequential emerging biosecurity challenge of the mid-2020s. The Council on Strategic Risks (CSR) 2025 Year in Review documents a year of rapid escalation in both capability and governance response.

Key developments in 2025 with direct 2026 implications:

The FY 2026 National Defense Authorization Act (NDAA), signed December 2025, contains multiple biotech and biosecurity provisions — the most significant being federal legislative attention to healthcare data privacy as a biosecurity issue.

This reflects growing recognition that genetic databases, clinical records, and laboratory information systems are not just privacy concerns but national security vulnerabilities.

Olvera (Biosecurity 2026, Lawrence Livermore National Laboratory) specifically recommends passage of dedicated federal cyberbiosecurity legislation that strengthens healthcare data privacy and cybersecurity standards across biomedical research institutions.

The CEPI (Coalition for Epidemic Preparedness Innovations) Biosecurity Strategy Implementation Plan (2025-2026) addresses vulnerabilities in preventing and mitigating biosafety and biosecurity risks in vaccine R&D and manufacturing.

The specific innovation: embedding biosecurity risk assessment into the vaccine development pipeline itself, rather than treating it as a separate compliance function. This "security by design" approach mirrors software security's shift from post-development audits to secure development lifecycle frameworks.

The core governance challenge — the Benevolent Assistance Dilemma: AI dramatically accelerates beneficial biological research (faster drug discovery, better pathogen surveillance, improved vaccine design) while simultaneously lowering the barrier for malicious actors to design novel biological threats.

Unlike nuclear weapons, biological capabilities cannot be geographically concentrated — the same AI tools, laboratory equipment, and genetic synthesis services used for beneficial research can be repurposed. Governance frameworks must therefore operate at the point of capability rather than the point of intent.

Three policy proposals with the strongest evidence base: 1. Mandatory AI-screening of DNA synthesis orders: Requiring DNA synthesis companies to use AI-powered screening tools to flag sequences with biological weapons potential before synthesis.

The International Gene Synthesis Consortium already has voluntary screening; the proposal is to make this mandatory, standardized, and AI-enhanced. Estimated coverage gap: approximately 20-30% of global synthesis capacity is currently unscreened. 2.

Biosecurity by design in AI biology tools: Requiring AI tools designed for biological research to include built-in guardrails against dual-use misuse, similar to how large language models have been modified to refuse weapons-design assistance. AlphaFold and similar protein structure tools represent the leading edge of this challenge. 3.

International Biological Weapons Convention (BWC) enhancement: The BWC lacks a verification protocol — the single largest structural gap in international biosecurity governance. The proposal (supported by multiple CSR researchers) is to add a verification annex modeled on IAEA safeguards, adapted for the distributed nature of biological research.